Pharmaron Beijing Co Ltd (3759) · Other

WuXi Biologics (Cayman) Inc (2269) · Other

The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.

12/18/2026, 12:00:00 AM

Livzon Pharmaceutical Group Inc (1513) · Other

Ex-dividend date on June 16, 2026, for the 2025 final cash dividend of RMB 14.3 per 10 shares, with payment on July 13, 2026, scheduled. This consistent dividend payout is estimated to have a minor positive impact on investor sentiment.

6/16/2026, 12:00:00 AM

Grand Pharmaceutical Group Ltd (512) · Other

Ex-dividend date for a proposed final dividend of HK$0.169 per share for the year ended December 31, 2025, on 2026-06-12 scheduled. Low importance as dividend ex-dates typically result in minor price adjustments.

6/12/2026, 12:00:00 AM

Hangzhou Tigermed Consulting Co Ltd (3347) · Other

Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.

6/2/2026, 12:00:00 AM

GRAIL Inc (GRAL) · Other

GRAIL to present additional data from the NHS-Galleri trial at the 2026 ASCO Annual Meeting on May 30, 2026, scheduled. High importance estimated as clinical data is a key valuation driver.

5/30/2026, 12:00:00 AM

ANTA Sports Products Limited (2020) · Other

Ex-dividend date for the final FY2025 dividend of HK$1.08 per share is scheduled for May 15, 2026.

5/15/2026, 12:00:00 AM